← Valneva SE (VALN) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Valneva SE (VALN)
Biological Products, (No Diagnostic Substances) · market cap $1.1B · as of 2026-07-07
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-19 (est.)
Earnings
Pipeline
5
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Valneva SE (VALN) is a specialty vaccine company with 713 employees and a ~$507M market cap trading at approximately $5.23. The company fields a multi-asset pipeline spanning SARS-CoV-2 (VLA2001, Phase 3), Chikungunya (VLA1553, Phase 3), Japanese encephalitis (IC51, Phase 3), Hepatitis C (IC41, Phase 2), and ventilator-associated pneumonia (IC43, Phase 2). The nearest disclosed catalyst is an August 11, 2026 earnings release.
The catalyst path
- 2026-11-19 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| VLA2001 | Phase 3 | SARS-CoV-2 Infection |
| IC41 | Phase 2 | Chronic Hepatitis C |
| IC51 | Phase 3 | Encephalitis |
| IC43 | Phase 2 | Pneumonia, Ventilator-Associated |
| VLA1553 | Phase 3 | Chikungunya Virus Infection |
Price & technical context
3-month
+13.0%
6-month
-5.9%
12-month
-51.6%
52-wk range
$4.78–$11.99
vs 50-day MA
-4.2%
vs 200-day MA
-17.7%
Realized vol
69.9%
Max drawdown
-60.8%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for VALN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.